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Abstract
Introduction: The Influenza Clinical Information Network (FLU-CIN) was established to gather detailed clinical and
epidemiological information about patients with laboratory confirmed A(H1N1)pdm09 infection in UK hospitals. This report
focuses on the clinical course and outcomes of infection in pregnancy.
Methods: A standardised data extraction form was used to obtain detailed clinical information from hospital case notes and
electronic records, for patients with PCR-confirmed A(H1N1)pdm09 infection admitted to 13 sentinel hospitals in five clinical
’hubs’ and a further 62 non-sentinel hospitals, between 11th May 2009 and 31st January 2010.Outcomes were compared for
pregnant and non-pregnant women aged 15–44 years, using univariate and multivariable techniques.
Results: Of the 395 women aged 15–44 years, 82 (21%) were pregnant; 73 (89%) in the second or third trimester. Pregnant
women were significantly less likely to exhibit severe respiratory distress at initial assessment (OR= 0.49 (95% CI: 0.30–0.82)),
require supplemental oxygen on admission (OR= 0.40 (95% CI: 0.20–0.80)), or have underlying co-morbidities (p-trend
,0.001). However, they were equally likely to be admitted to high dependency (Level 2) or intensive care (Level 3) and/or to
die, after adjustment for potential confounders (adj. OR = 0.93 (95% CI: 0.46–1.92). Of 11 pregnant women needing Level 2/3
care, 10 required mechanical ventilation and three died.
Conclusions: Since the expected prevalence of pregnancy in the source population was 6%, our data suggest that pregnancy
greatly increased the likelihood of hospital admission with A(H1N1)pdm09. Pregnant women were less likely than non-
pregnant women to have respiratory distress on admission, but severe outcomes were equally likely in both groups.
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Introduction
Increased mortality and morbidity in pregnant women have
been observed during previous pandemics and influenza epidemics
[1–4] and it is widely accepted that pregnancy is a risk factor for
hospitalisation following influenza infection. [5,6] The effects of
maternal influenza infection are, however, not fully understood,
though postulated to result from a combination of immunological
and physiological changes. [7,8].
In April 2009, an outbreak of novel influenza A(H1N1)pdm09
began in Mexico and on June 11th the World Health Organization
(WHO) declared a pandemic. The Department of Health,
England, established an Influenza Clinical Information Network
(FLU-CIN) at the outset in order to gather detailed clinical and
epidemiological information from hospitalised A(H1N1)pdm09
cases in the UK. [9,10] Previous reports from other, similar case
series have demonstrated an increased risk of hospitalisation
among pregnant women [11] but there are inconsistencies in the
apparent severity of outcomes. Whilst some suggest that hospital-
ised pregnant women have a decreased risk of admission to
intensive care [11–14], others report an increased risk of severe
illness. [15,16].
This study describes the characteristics of pregnant women in
the FLU-CIN cohort hospitalised with confirmed A(H1N1)pdm09
infection. It compares pandemic influenza outcomes with non-
pregnant women of the same age, adjusting for co-morbidities and
illness severity at admission, which have not always been taken
fully into account by other studies.
Methods
The FLU-CIN project is described in further detail in an earlier
paper. [9] FLU-CIN was an ‘emergency’ study with a purposive
sampling frame based around 13 sentinel hospitals in five clinical
‘hubs’ (Nottingham, Leicester, Imperial College London, Sheffield
and Liverpool), with contributions from a further 45 non-sentinel
hospitals in England and 17 in Scotland, Wales and Northern
Ireland. This included five children’s hospitals and five respiratory
tertiary referral centres (three with facilities for Extra Corporeal
Membrane Oxygenation (ECMO)). Children’s hospitals and
tertiary referral centres were not mutually exclusive; one of three
ECMO centres was a children’s hospital. Trained staff reviewed
the hospital case notes and electronic records of patients with
A(H1N1) pdm09 confirmed by real-time reverse-transcriptase
polymerase chain reaction (PCR), and completed a common,
standardised data extraction form. [9,10] From this source cohort,
all women aged 15–44 years were selected (childbearing age as
defined by the National Association for Public Health Statistics
and Information Systems). [17] Data collected included demo-
graphic characteristics, past medical history (including co-morbid-
ities as denoted by the Charlson’s co-morbidity index [18,19] and
obesity) vaccination history, pre-admission care, clinical presenta-
tion, requirement for high dependency (Level 2) or intensive care
(Level 3)admission, gestational age at admission, and maternal and
foetal outcomes. High dependency (Level 2) care was defined as
patients requiring more detailed observation or intervention
(including support for a single failing organ system and those
‘stepping down’ from higher levels of care),and intensive (Level 3)
care was defined as patients requiring advanced respiratory
support alone or basic respiratory support together with support
of at least two organ systems (including all complex patients
requiring support for multi-organ failure). Any missing data were
coded as dummy variables and reporting of information otherwise
assumed to be complete.
Anonymised data were analysed using STATA (Version 11.0,
StataCorp Inc.) and univariate analyses performed using logistic
regression to compare factors associated with length of hospital
stay, need for higher level care (admission to Level 2 or Level 3
care), death and combined severe outcomes (defined as Level 2/
Level 3 admission or death) in pregnant and non-pregnant women
of similar age. Multivariable regression analysis was conducted to
adjust for factors that could potentially confound the relationship
between pregnancy and pandemic influenza outcomes, using a
conceptual model based on a combination of expert opinion and
existing evidence. [10] Potential confounding variables selected for
inclusion were co-morbidities (using Charlson’s Co-morbidity
Index) [18,19], recorded obesity (not classified under Charlson),
in-hospital antiviral use and severity of illness at admission
(indicated by severe respiratory distress and defined as severe
breathlessness (e.g. unable to complete sentences in one breath,
use of accessory muscles, supra-clavicular recession, tracheal tug or
feeling of suffocation), and specified in the FLU-CIN questionnaire
as CAT triage criteria A [20]). Missing values were coded
separately as a dummy variable for inclusion in the multivariable
logistic regression model. Sensitivity analyses were performed
adding pre-admission antiviral use as a covariate in the model and
restricting analysis to women without underlying co-morbidities.
Results
Characteristics of Pregnant Cohort
The FLU-CIN cohort consisted of 1,520 cases with PCR
confirmed A(H1N1)pdm09 infection. Three hundred and ninety-
five (26%) were women aged 15–44 years, 82 of whom (21%) were
pregnant, compared with an expected prevalence of 6% based on
the source population. [9,10] One additional pregnant female
identified in the full FLU-CIN cohort was excluded from the
current analysis as she was aged 14 years.
On admission, six of the 82 pregnant women (7%) were in the
first trimester, 33 (40%) in the second and 40 (49%) in the third
(missing data = 3). Fifty-nine (72%) pregnancies were reported to
be single, and one multiple (missing data = 22). Twenty-seven
(33%) were admitted to hospital during the first wave of the
pandemic and 55 (67%) during the second wave. The interval
between onset of symptoms and admission ranged from 0–17 days
(median 2.0; interquartile range 1–4; missing data = 29). The
main findings of the univariate analysis comparing the character-
istics of pregnant and non-pregnant women aged 15–44 are
presented in Table 1. Pregnant women were significantly less likely
to exhibit severe respiratory distress at initial hospital assessment
or require supplemental oxygen on admission than non-pregnant
women of a similar age.
Underlying Co-morbidities
Pregnant women were significantly less likely to have other co-
morbid illnesses than non-pregnant women. The most prevalent
condition amongst those pregnant (approximately 80% of all
Influenza A(H1N1)pdm09 Infection in Pregnant Women
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recorded co-morbidities) was asthma, reported in 17 (21%)
women. In contrast, asthma was reported by 128 (41%) non-
pregnant women of similar age.
Use of Anti-viral Medication
Fewer pregnant women were prescribed pre-admission or in-
hospital anti-viral medication when compared with non-pregnant
women, although neither of these findings was statistically
significant. Sixty-one (74%) pregnant women were prescribed
anti-viral medication in hospital, compared with 253 (81%) of
non-pregnant women. There was insufficient information to
comment on the time from symptom onset to treatment for either
group. Nineteen pregnant women (23%) had seen a General
Practitioner (GP) with influenza-like symptoms prior to admission,
compared with 90 (29%) non-pregnant women (missing da-
ta = 196)(p = 0.29). Five of the nineteen (26%) pregnant women
who had seen a GP were prescribed anti-viral medication in the
community, compared with 24 of the 90 (27%) non-pregnant
women (p = 0.98).
Influenza Vaccination
Pandemic vaccination status was generally poorly recorded.
Fifty-four pregnant women were admitted prior to the 23rd
October 2009 and would either not have had the opportunity to
be vaccinated or would not have seroconverted (even if vaccinated)
prior to illness onset. Of the remaining 28, only two (7%) were
reported to have received the vaccine, whereas seven (25%) were
reported not to have received it (missing data = 19).
Maternal Outcomes
Sixteen (20%) pregnant women were admitted within 2 days of
symptom onset compared with 82 (26%) of non-pregnant women
(p = 0.36, missing data = 120). Eleven (13%) pregnant women had
radiological evidence of pneumonia compared with 51 (16%) non-
pregnant women (p = 0.53).
After adjustment for co-morbidities (including recorded obesity),
severity of illness on admission, and in-hospital antiviral use,
pregnant women were no more likely to require a hospital stay $2
days (OR 0.94, 95% CI 0.48–1.86, p = 0.865) or to experience
severe outcomes including Level2/3 admission or death (OR 0.93,
95% CI 0.46–1.92, p = 0.808) (Table S1). In the sensitivity analysis
where pre-admission antiviral use was added as an additional
covariate, the results for all outcomes measures were almost
identical (Table S2).There was also no statistically significant
difference in the risk of severe outcomes (Level 2/3 admission or
death) by wave of the pandemic when comparing pregnant and
non-pregnant women (first wave unadj. OR 1.24, 95% CI 0.42–
3.69, p = 0.69; second wave unadj. OR 0.78, 95% CI 0.32–1.88,
p = 0.58).
Of the 11 pregnant women (13%) requiring Level 2/3 care,
only three (27%) had underlying co-morbidities, two with diabetes
mellitus and one with asthma. Ten (91%) required mechanical
Table 1. Comparison of patient characteristics for pregnant and non-pregnant women of child-bearing age from the FLU-CIN
cohort.
Characteristic Value Pregnant, n (%) Non-pregnant, n (%) OR* (95% CI) P value
Age (years) 15 0 (0.0) 6 (1.9) 0.99{ (0.96–1.02) P trend
0.370
16–24 31 (37.8) 118 (37.7)
25–35 39 (47.6) 101 (32.3)
36–44 12 (14.6) 88 (28.1) 0.99{ (0.96–1.02) P trend 0.370 0.370
Charlson index score 0 62 (75.6) 152 (48.6) 1.00
1–2 19 (23.2) 151 (48.2) 0.31 (0.18–0.54)
3–5 1 (1.2) 10 (3.2) 0.25 (0.03–1.96)
.5 0 (0.0) 0 (0.0) – P trend ,0.001
Obesity – 3 (3.7) 15 (4.8) 0.75 (0.21–2.67) 0.662
Supplemental oxygen – 11 (13.4) 87 (27.8) 0.40 (0.20–0.80) 0.009
Severe resp. distress$ – 27 (32.9) 156 (49.8) 0.49 (0.30–0.82) 0.007
CRP ,100 38 (46.3) 149 (47.6) 1.00
$100 9 (11.0) 34 (10.9) 1.04 (0.46– 2.35) 0.929
Missing 35 (42.7) 130 (41.5) – –
Pneumonia (radiological) – 11 (13.4) 51 (16.3) 0.80 (0.39–1.60) 0.52
Admission within 2 days – 16 (19.5) 82 (26.2) 0.74 (0.39–1.41) 0.36
Missing 29 (35.4) 91 (29.1) – –
Pre-admission antiviral – 8 (9.8) 46 (14.7) 0.63 (0.28–1.39) 0.25
In-hospital antiviral – 61 (74.4) 253 (80.8) 0.69 (0.30–1.22) 0.20
Length of stay (days) ,2 15 (18.3) 47 (15.0) 1.00 –
$2 61 (74.4) 234 (74.8) 0.82 (0.43–1.56) 0.539
Missing 6 (7.3) 32 (10.2) – –
*Unadjusted odds ratio.
$Indicated by CAT triage criteria A20.
{Age fitted as a continuous variable in the logistic regression model.
doi:10.1371/journal.pone.0041638.t001
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ventilation compared with 32 (70%) of the 46 non-pregnant
women admitted to Level 2/3 care, however the difference was
not statistically significant (p = 0.15). Seven of the 11 pregnant
women had radiological evidence of pneumonia (64%), compared
with 25 (54%) non-pregnant women in Level2/3 care (p = 0.58).
Only one of the 11 (9%) pregnant women had been admitted to
hospital within two days of onset (missing data = 4) compared with
13 of 46 (28%) non-pregnant women (missing data = 17) (p = 0.14).
Seven of the 11 (64%) pregnant women admitted to Level 2/3
care were prescribed anti-viral medication in-hospital compared
with 38 of 46 (83%) non-pregnant women (p= 0.17); 2 (18%)
pregnant women received treatment pre-admission, compared
with 6 (13%) non-pregnant women (p = 0.66).
Three pregnant women died during admission, two with
pneumonia and one following complications post delivery
(coagulopathy, hypotension and cerebral infarction). There was
no difference in the likelihood of death when compared with non-
pregnant women (3 of 82 (4%) vs 11 of 313 (4%)) before (unadj.
OR 1.04, 95% CI 0.28- 3.83) and after adjustment for co-
morbidity, severity of illness on admission and in-hospital antiviral
use (adj. OR 1.18, 95% CI 0.31- 4.53). In addition there was no
difference in case-fatality between pregnant or non-pregnant
women who were sick enough to require mechanical ventilatory
support (2 of 10 (20%) vs. 7 of 32 (22%): unadj. OR 0.89, 95% CI
0.15–5.20).
Overall, pregnant women hospitalised with A(H1N1)pdm09
infection were no more likely to experience severe outcomes (Level
2/3 admission or death) when compared with non-pregnant
women of a similar age (adj. OR 0.93, 95% CI: 0.46–1.92).
Similarly, the sensitivity analysis considering only women without
prior co-morbidities (Charlson index score = 0; pregnant = 62;
non-pregnant = 152) and designed to exclude any residual
confounding effects, also found no evidence that pregnant women
had an increased risk of severe outcome either before (unadj. OR
0.92, 95% CI 0.47–1.83) or after adjusting for disease severity at
admission (adj. OR 0.97, 95% CI: 0.39–2.45).
Foetal Outcomes
Data regarding foetal outcomes were taken from free text notes.
Sixteen babies were delivered during admission, ten to mothers
admitted for predominantly obstetric reasons and four to mothers
admitted for predominantly respiratory illness (missing data = 2),
although clearly it is impossible to rule out influenza having a
detrimental effect on a pregnancy and precipitating an obstetric
issue. Three of the four mothers with apparent respiratory illness
required Level 2/3 care and delivered pre-term babies, two
requiring emergency caesarean section and one induced labour
resulting in a still-birth. The fourth mother required emergency
caesarean section but not Level 2/3 care, and delivered at term. In
comparison, none of the ten mothers admitted predominantly for
obstetric reasons required Level 2/3 care and only one delivered a
pre-term baby by elective caesarean section.
Discussion
This is the only study of which we are aware to present findings
amongst pregnant women hospitalised during both waves of the
2009 pandemic in the UK. In addition, it is unique in its comparison
of severe outcomes for pregnant and non-pregnant hospitalised
cases of childbearing age with confirmed A(H1N1)pdm09, following
careful adjustment for severity of illness at admission and other
confounding variables.
The data collected were not independently verified and there
was no attempt to obtain missing fields or follow-up cases, which
may have resulted in some reporting bias. However, there was full
extraction from case records, and comparison with non-pregnant
women of the same age that also had A(H1N1)pdm09 infection,
which illuminates the course of A(H1N1)pdm09 in pregnancy.
The high prevalence of pregnancy in this cohort of women aged
15–44 years, aligns with previous studies which suggest a marked
increase in the likelihood of admission with A(H1N1)pdm09 when
compared with non-pregnant women of similar age. [11,15] In
accordance with other published case series, [12,13,16,21,22] the
majority of women were in the second and third trimesters of
pregnancy, suggesting an increased risk of hospitalisation in the
later stages of pregnancy, although this may be confounded by a
failure to recognise some early pregnancies. Pregnant women were
significantly less likely to have underlying co-morbidities than non-
pregnant women of childbearing age, emphasising the importance
of pregnancy itself as a risk factor for hospitalisation. But despite
the increased likelihood of admission for pregnant women, we
found little evidence of greater illness severity at initial hospital
assessment, as suggested by our findings that pregnant women
were less likely to present with respiratory distress or require
supplemental oxygen on admission. This does not appear to be
confounded by the use of antiviral medication, since pregnant
women were, if anything less likely to receive this pre-admission.
Other factors such as a lower threshold, or alternative primary
indication for hospital admission (such as obstetric complication)
may be of more importance. The reason for admission was,
however, not always reported making it difficult to explore this
further by stratified analysis. Three quarters (74%) of the pregnant
cohort required a hospital stay of two days or more, suggesting
that ‘front door’ anxiety for the pregnant patient may not fully
explain the increased admission rate.
There was no evidence of a greater likelihood of severe
outcomes in pregnant women as indicated by length of stay,
requirement for Level 2/3 care or mortality. This held true even
when adjusted for severity of illness on admission and underlying
co-morbidities, or when comparing outcomes in women with no
co-morbidities, through sensitivity analysis. The burden of
mortality in other cohorts of pregnant women hospitalised with
A(H1N1)pdm09 ranges from 1% [14] to 6% [13] and is not
dissimilar from that observed in this case series. The risk of
admission to intensive care does, however, appear to vary, some
case series reporting this to be lower [11–14] and others higher
[15] when compared with infected non-pregnant women of a
similar age. This may be explained by different criteria for
admission to Level 2/3 care which exist in different countries,
although even when considering only the most seriously ill women
who required mechanical ventilation, there was still no apparent
increase in the risk of death for pregnant women in this cohort.
Other studies have found pregnant women with confirmed
A(H1N1)pdm09 in critical care experience higher rates of viral
pneumonia despite a lack of difference in mortality [23], but no
statistically significant difference was observed in this cohort.
Although this suggests that once hospitalised, outcomes for women
of childbearing age in the FLU-CIN cohort were similar regardless
of pregnancy, caution must be exercised due to the smaller
number of observations and potential lack of power with which to
detect a true underlying effect.
Inconsistency in the estimated size of effect of pregnancy on
severity of outcomes following A(H1N1) pdm09 infection may also
reflect a marked variation in the prevalence of underlying co-
morbidities and residual confounding; not all reports adjusted for
presence of co-morbidities in the same way.[11–15] It is possible
that differences in the ethnic composition of the populations
considered may also have a role to play.
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Despite the apparent lack of effect of pregnancy on severe
outcomes once hospitalised, it seems that influenza infection in
pregnancy nevertheless has serious implications for maternal
health since ten of the 11 pregnant women admitted to Level 2/3
care in this cohort required mechanical ventilation, and only three
had co-morbid illnesses. Further studies with greater power are
however required in order to definitively conclude this. Where co-
morbidities were reported for pregnant women, asthma was most
prevalent, which again aligns with observations in other case
series. [22,24] Other data also suggest that A(H1N1)pdm09 cases
with asthma experienced a reduced likelihood of severe outcome
after admission. [9,10].
Pregnant women were quickly identified as a priority group for
both early anti-viral treatment and vaccination in the UK, as
elsewhere. There was widespread availability of antiviral drugs in
the community following establishment of a National Pandemic
Flu Service in July 2009 [25], and whilst 74% of pregnant women
in this cohort were prescribed anti-viral medication only 10% (8/
82) received these in the community prior to admission. It is
difficult to determine whether earlier treatment would have altered
the observed outcomes, but delayed treatment has been associated
with an increased risk of severe illness in pregnant women in
previous hospitalised case series. [14,16,22] Although differences
in antiviral drug uptake between pregnant and non-pregnant
women are small, this suggests an ongoing need to emphasise the
use of early anti-viral therapy on suspicion of influenza and
promote its acceptability for use during pregnancy in a pandemic
situation. [26] Evidence regarding the safety of Oseltamivir in
pregnancy is, however, limited [27,28] and further studies which
focus on the risk of potential adverse events would clearly be of
value.
Vaccination status was inconsistently recorded in medical notes
and may in part be explained by the fact that the pandemic
vaccine was not introduced in the UK until late October 2009, so
54 of the pregnant women in the cohort would either not have had
the opportunity to be vaccinated, or would not have seroconverted
(if vaccinated), prior to illness onset. Although there were large
amounts of missing data, the fact that only 7% of those for whom
the pandemic vaccine would have been available in time to have
offered protection were noted to have had it, compared with 25%
noted not to have had it, suggests that coverage was low, as
observed in other hospitalised cohorts. [29,30] This further
highlights the need to emphasise existing public health policy,
and for healthcare workers, especially GPs and midwives, to
advocate for vaccination against influenza during pregnancy.
Most women did not deliver during admission and were
therefore not followed up as part of the FLU-CIN protocol. Of the
sixteen women who did deliver during admission, three of the four
who were admitted primarily with respiratory illness delivered pre-
term babies and two mothers died post-partum. In comparison
there was only one pre-term delivery and one maternal death
amongst the ten women admitted for predominantly obstetric
reasons. Adverse foetal outcomes following maternal influenza
infection have previously been described, [30,31] and although
these data must be interpreted with caution, they suggest a
potential short-term impact of influenza infection on foetal as well
as maternal health.
Conclusions
As judged by the need for hospital admission, this study
corroborates previous evidence that pregnancy itself was a risk
factor for significant illness due to A(H1N1)pdm09 infection. There
is, however, little evidence from our data to suggest that maternal
outcomes were any more or less severe than for non-pregnant
women of a similar age in the UK, even when severity of illness at
admission (indicated by respiratory distress), additional underlying
co-morbidities and in-hospital anti-viral use were taken into
account. However, some caution must be exercised due to the
small numbers in the study. Despite national recommendations for
early anti-viral treatment and vaccination, the former were either
not accessed or not offered to one quarter of the pregnant women in
this cohort at any point in the care pathway; and vaccine uptake was
low amongst those for whom it was available. Both have been shown
to be effective in reducing the frequency [32] or severity of
respiratory illness [4] in pregnant women and there is a need to
continue to advocate and emphasise their role in optimal obstetric
care.
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